Redeye: Doro - Continuing convalescence

We have updated our research of Doro following the company's Q2 report. Overall, the Q2 earnings release followed the same trends as the previous quarters and we have therefore not changed our thinking with regards to our view of the Doro case.

Read more in the Research Update by Viktor Westman at: 

Start following companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking.